Robert W. Baird Raises Axon Enterprise (NASDAQ:AXON) Price Target to $400.00

Axon Enterprise (NASDAQ:AXON - Free Report) had its price objective hoisted by Robert W. Baird from $360.00 to $400.00 in a research report released on Tuesday, Benzinga reports. Robert W. Baird currently has an outperform rating on the biotechnology company's stock.

Several other brokerages have also weighed in on AXON. Northland Securities lifted their price objective on Axon Enterprise from $330.00 to $365.00 and gave the stock an outperform rating in a report on Thursday, August 8th. Needham & Company LLC reissued a buy rating and issued a $400.00 price target on shares of Axon Enterprise in a research report on Wednesday, August 7th. Jefferies Financial Group began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They issued a buy rating and a $385.00 price objective for the company. Craig Hallum boosted their target price on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a buy rating in a report on Wednesday, August 7th. Finally, Barclays increased their target price on Axon Enterprise from $381.00 to $387.00 and gave the stock an overweight rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $361.15.

Axon Enterprise Stock Performance

AXON traded down $5.04 during midday trading on Tuesday, reaching $359.35. The company had a trading volume of 324,389 shares, compared to its average volume of 518,497. Axon Enterprise has a 12-month low of $189.12 and a 12-month high of $378.89. The business has a 50-day moving average price of $332.91 and a two-hundred day moving average price of $312.13. The stock has a market cap of $27.16 billion, a PE ratio of 104.80, a P/E/G ratio of 9.50 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. During the same quarter in the prior year, the business earned $0.80 earnings per share. Axon Enterprise's revenue for the quarter was up 34.5% on a year-over-year basis. On average, sell-side analysts expect that Axon Enterprise will post 1.79 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other news, CEO Patrick W. Smith sold 80,300 shares of Axon Enterprise stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the completion of the sale, the chief executive officer now owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Patrick W. Smith sold 80,300 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $371.78, for a total value of $29,853,934.00. Following the transaction, the chief executive officer now owns 3,015,366 shares of the company's stock, valued at approximately $1,121,052,771.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Matthew R. Mcbrady sold 2,000 shares of Axon Enterprise stock in a transaction on Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the sale, the director now directly owns 4,892 shares of the company's stock, valued at $1,783,916.72. The disclosure for this sale can be found here. Over the last quarter, insiders sold 286,832 shares of company stock valued at $104,350,029. Company insiders own 6.10% of the company's stock.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors have recently modified their holdings of AXON. ICA Group Wealth Management LLC bought a new position in shares of Axon Enterprise during the 4th quarter valued at $26,000. Blue Trust Inc. grew its stake in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company's stock valued at $27,000 after buying an additional 79 shares during the last quarter. Trivant Custom Portfolio Group LLC bought a new position in shares of Axon Enterprise during the first quarter valued at about $31,000. First PREMIER Bank bought a new stake in shares of Axon Enterprise in the 1st quarter valued at about $33,000. Finally, Blue Bell Private Wealth Management LLC bought a new stake in shares of Axon Enterprise in the 1st quarter valued at about $41,000. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.